SCHEMBL18632529

SCHEMBL18632529

O=c1[nH]nc2ccc(-c3ccccc3Cl)c(Oc3ccccc3)n12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 5/20 0.38
HSP90AA1 P07900 2/20 0.35
NSD2 O96028 1/20 0.35
HKDC1 Q2TB90 1/20 0.35
TLR9 Q9NR96 1/20 0.35
ALPL P05186 2/20 0.35
NPC1 O15118 1/20 0.35
TP53 P04637 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
HPGD P15428 1/20 0.35
CYP2C19 P33261 1/20 0.35
RAB9A P51151 1/20 0.35
NR1H2 P55055 1/20 0.35
NR1H3 Q13133 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CNR1 P21554 2/20 0.35
CNR2 P34972 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18632540 0.78 CNR1 (0.36) NOTUMHSP90AA1CNR1CNR2PDE5A
SCHEMBL18632543 0.78 PDE1A (0.38) NOTUMPDE5APDE1APDE1BPDE3B
SCHEMBL18632515 0.70 CHEK1 (0.39) NOTUMCYP1A2PDE5APDE1APDE1B
SCHEMBL18632513 0.65 SCN5A (0.49) NOTUMALPLNPC1TP53CYP1A2
SCHEMBL18632518 0.64 SCN5A (0.51) NOTUMNPC1RAB9APDE5APDE3B
SCHEMBL5475521 0.64 CHEK1 (0.52) NOTUMCHEK1
SCHEMBL8502222 0.63 HTT (0.48) NPC1CYP1A2HPGDCYP2C19RAB9A
SCHEMBL9120422 0.62 HSD11B1 (0.58) NOTUMHSP90AA1NPC1RAB9ASMN1; SMN2
SCHEMBL11822396 0.61 CYP2A6 (0.52) HSP90AA1NSD2HKDC1TLR9ALPL
SCHEMBL1602164 0.60 CHEK1 (0.54) NOTUMRAB9ASMN1; SMN2PDE5APDE1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170081323-A1 Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease HOFFMANN LA ROCHE (CH) 2017-03-23 US disclosed
US-20170081323-A1 Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease HOFFMANN LA ROCHE (CH) 2017-03-23 US disclosed
WO-2017046318-A1 TRIAZOLONES DERIVATIVES FOR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2017-03-23 WO disclosed
US-20170081323-A1 Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease HOFFMANN LA ROCHE (CH) 2017-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170081323-A1 Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease OAT, XDH, MAPT NOTUM 541/4885HSP90AA1 4017/4885NSD2 3157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.